Skip to main content
Premium Trial:

Request an Annual Quote

Co-Diagnostics COVID-19 Test Approved by UK Regulators

NEW YORK – Co-Diagnostics said on Thursday its Logix Smart SARS-CoV-2 two-gene multiplex test has been approved in the UK.

The test has been validated according to regulations from the UK's Health Security Agency and can be sold in the UK, the Salt Lake City-based firm said, adding it has been validated for use with several sample types, including saliva. Additionally, bronchoalveolar lavage, sputum, tracheal aspirate, nasopharyngeal and oropharyngeal swabs can be used, according to the firm's website.

The RT-PCR-based test leverages Co-Diagnostics' CoPrimer technology to qualitatively detect the RdRp and E genes from the RNA of SARS-CoV-2.

Co-Diagnostics noted that the test is being offered in the UK by its distributor there, Client Life Science.

In June, Co-Diagnostics's Logix Smart SARS-CoV-2 DS test received CE marking.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.